Boston Scientific announced on Oct. 8 that it had provided additional financing for MValve Technologies, a company that is developing a percutaneous mitral valve replacement system.
Boston Scientific said it has an exclusive option to acquire MValve Technologies, a privately held corporation founded in 2011 with operations in San Diego and Herezeliya, Israel.
MValve Technologies, which has received funding from Boston Scientific since 2012, plans to use some of the new financing to fund a trial for the MValve docking system for transcatheter mitral valve replacement in patients with mitral regurgitation.
With that approach, Boston Scientific’s Lotus valve is deployed inside the MValve docking system, which is not available for sale. The approach is intended to treat mitral regurgitation, the most common type of heart valve disorder.
The Lotus aortic valve system is not FDA-approved and is not available for sale in the U.S., but it is approved in Europe. The system includes a pre-loaded, stent-mounted tissue valve prosthesis and catheter delivery system for guidance and percutaneous placement of the valve.
On Oct. 5, MValve Technologies announced the first human implantation of its docking system and the Lotus valve was completed successfully in a 72 year old man with valve disease at the University Clinic in Bonn, Germany.
Maurice Buchbinder, MD, an interventional cardiologist and founder and medical director of MValve Technologies, was present at the procedure.